Contraceptives Market (Product: Contraceptive Drugs [Oral Contraceptives, Contraceptive Injectable, and Topical Contraceptive Patch] and Contraceptive Devices [Male Contraceptive Devices and Female Contraceptive Devices]; and Distribution Channel: Hospitals Pharmacies, Independent Pharmacies, Online Pharmacies, Clinics, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028
Published Date
No. of Pages
Description
Contraceptives Market Outlook 2028
The global contraceptives market was valued at US$ 893.9 Mn in 2020
It is estimated to expand at a CAGR of 15.5% from 2021 to 2028
The global contraceptives market is expected to cross the value of US$ 2.7 Bn by the end of 2028
Analysts’ Viewpoint on Contraceptives Market Scenario
Birth spacing methods amid the ongoing COVID-19 pandemic include precise advice on lactation amenorrhoea method (LAM) to enhance its efficacy, barrier methods such as condoms, and plentiful supplies of oral progestin-only pill, among others. The global contraceptives market is highly fragmented, with the presence of a large number of international as well as regional players. Since there is a lack of awareness about the advantages of contraceptives in developing economies, market stakeholders should initiate collaborative agreements with governments to educate women as well as related individuals about different alternatives. Manufacturers should increase the production of affordable contraceptive options to boost their uptake in developing economies.
High Prevalence of Sexually Transmitted Infections Propels Demand for Contraceptives
A number of international and national organizations have initiated STI (sexually transmitted infections) awareness campaigns. Additionally, regulatory agencies in the U.K., such as the Medicines and Healthcare Regulatory Agency (MHRA), have approved injectable contraceptives. These approvals for women and men are expected to boost the growth of the global contraceptive market, particularly in developed countries.
Increase in adoption of innovative contraceptive technologies in emerging countries is another factor propelling the global contraceptives market. People across the world have become more aware about the need of family planning.
Birth Spacing Helps Reduce Burden on Healthcare Systems amid COVID-19 Pandemic
The COVID-19 pandemic has heightened the importance for family planning since most people have been spending time indoors. Manufacturers in the contraceptives market are capitalizing on this opportunity to ensure uninterrupted supply of oral contraceptives, contraceptive injectables, and contraceptive devices. Healthcare organizations are stressing on the advantages of birth spacing during the ongoing pandemic, since avoiding pregnancy during such uncertain times is wise for women not only on a personal level but also from a public health perspective in terms of not adding to overburdened healthcare systems. Manufacturers are increasing efforts to prevent stock-outs for implants, oral contraceptive pills, and copper intrauterine devices.
Comprehensive Product Portfolio Allows Stakeholders to Expand Income Sources
The contraceptives market is likely to provide new vendors significant growth prospects, particularly in emerging countries. These companies can raise awareness and initiate activities about the usage of contraceptive devices. This is projected to increase contraceptive sales. Moreover, these new providers intend to expand their product offerings by introducing enhanced contraceptive devices. This is anticipated to boost the growth of the market.
Oral (pill) contraceptives, topical contraceptives, and injectable contraceptives are various types of contraceptives. Contraceptive devices, on the other hand, include condoms, intrauterine devices (IUD), vaginal rings, implants, patches, diaphragms, sponges, etc. The barrier method, particularly condoms, is the most common form of artificial contraception.
The global contraceptives market is expected to be driven by increase in efforts by governments to raise awareness about the negative effects of population growth and unwanted pregnancies.
Lack of Knowledge about Advantages of Contraceptives Hampers Market Growth
Women with unmet contraception needs rarely state that they are unaware of contraception, do not have access to a source of supply, or that it is too expensive. Women of Asia use modern contraception at a lower rate than the global average. In Asia, majority of unintended pregnancies is caused by the use of traditional contraception or the lack thereof, which results in induced unsafe abortion.
Key barriers to modern contraceptive practice among women in Asia are cultural attitudes, lack of knowledge about methods and reproduction, socio-demographic factors, and healthcare barriers. Lack of knowledge and access could be the most straightforward issues to address in this market. Hence, participants in the market should collaborate with governments to increase awareness about the advantages of contraceptives, which holds potential to boost product sales.
U.S. Sets Benchmark for Contraceptive Innovation and Collaborative Agreements
Key players in the global contraceptives market are engaged in regulatory approvals, innovations in technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global contraceptives market. A few expansion strategies adopted by players operating in the global contraceptives market are announcing the generic versions of vaginal ring in the U.S. The launch of such vaginal rings can be expected to drive the contraceptives market.
Healthcare organizations are launching global strategies for accelerating the abolition of cervical cancer. This is expected to augment the global contraception devices market. At the same time, manufacturers are investing in R&D to increase availability of FDA (Food and Drug Administration)-approved contraceptive options.
Contraceptives Market: Overview
According to Transparency Market Research’s latest report on the global contraceptives market for the historical period 2017–2018 and forecast period 2019–2027, decline in prices and increase in access to contraceptives are projected to drive the global contraceptives market during the forecast period
Rise in Prevalence of Sexually Transmitted Diseases Drives Demand for Contraceptive Tablets and Other Forms of Contraception
A number of international and national organizations have initiated STI awareness campaigns. Additionally, regulatory agencies in the U.K., such as the Medicines and Healthcare Regulatory Agency (MHRA), have approved injectable contraceptives. These approvals for women and men are expected to boost the growth of the global contraceptive market, particularly in developed countries.
Increase in adoption of innovative contraceptive technologies in emerging countries is another factor propelling the global contraceptives market. People across the world have become more aware about the need of family planning.
Entry of New Vendors with Advanced Contraceptive Methods: Key Driver
The global contraceptives market is likely to provide new vendors significant growth prospects, particularly in emerging countries. These companies can raise awareness and initiate activities about the usage of contraceptive devices. This is projected to increase contraceptive sales. Moreover, these new providers intend to expand their product offerings by introducing enhanced contraceptive devices. This is anticipated to boost the growth of the global contraceptives market.
Lack of Awareness about Application of Contraceptive Devices in Emerging Countries
Women with unmet contraception needs rarely state that they are unaware of contraception, do not have access to a source of supply, or that it is too expensive. Women of Asia use modern contraception at a lower rate than the global average.
In Asia, majority of unintended pregnancies are caused by the use of traditional contraception or the lack thereof, which results in induced unsafe abortion
Key barriers to modern contraceptive practice among women in Asia are cultural attitudes, lack of knowledge about methods and reproduction, socio-demographic factors, and healthcare barriers. Lack of knowledge and access could be the most straightforward issues to address in the global contraceptives market.
Competition Landscape
This report profiles major players in the global contraceptives market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
The global contraceptives market is highly fragmented, with the presence of a large number of international as well as regional players
Leading players operating in the global contraceptives market are
- Merck & Co., Inc., Cipla, Inc.
- Allergan plc
- Bayer AG
- HLL Lifecare Limited
- Mankind Pharma
- Pfizer, Inc.
- Teva Pharmaceutical Industries Ltd.
- Mithra Pharmaceuticals
- Janssen Pharmaceutical Company
- Reckitt Benckiser Group plc., etc.
Key Developments
Key players in the global contraceptives market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global contraceptives market. A few expansion strategies adopted by players operating in the global contraceptives market are:
On January 14, 2021, Teva Pharmaceuticals announced the generic version of NuvaRing (etonogestrel and ethinyl estradiol) vaginal ring in the U.S. The launch of such vaginal rings can be expected to drive the contraceptives market.
On November 17, 2020, the World Health Organization launched global strategies for accelerating the abolition of cervical cancer. This is expected to augment the global contraception devices market.
On May 22, 2020, Evofem Biosciences, Inc. announced that the U.S. Food and Drug Administration had approved Phexxi, a new contraceptive method
The report on the global contraceptives market discussed individual strategies, followed by company profiles of manufacturers of contraceptives devices. The competition landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global contraceptives market.
Key Questions Answered in Contraceptives Market Report
- What is the scope of growth of product companies in the global contraceptives market?
- What will be the Y-o-Y growth of the global contraceptives market between 2017 and 2028?
- What is the influence of changing trends in technologies on the global contraceptives market?
- Will North America to be the most profitable market for contraceptives devices providers?
- Which factors are anticipated to hamper the growth of the global contraceptives market during the forecast period?
- Which are the leading companies in the global contraceptives market?
Contraceptives Market – Segmentation
Product
- Contraceptive Drugs
- Oral Contraceptives
- Combined Contraceptives
- Mini-pills
- Contraceptive Injectable
- Topical Contraceptive Patch
- Contraceptive Devices
- Male Contraceptive Devices
- Female Contraceptive Devices
- Tissue Engineering
Distribution Channel
- Hospitals Pharmacy
- Public
- Private
- Independent Pharmacy
- Online Platform
- Clinics
- Others
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
TABLE OF CONTENT
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Contraceptives Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Key Market Indicators
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunity
4.5. Global Contraceptives Market Analysis and Forecast, 2017–2028
4.5.1. Market Revenue Projections (US$ Mn)
4.6. Global Contraceptives Market - Global Supply Demand Scenario
4.7. Porter’s Five Force Analysis
4.8. Value Chain Analysis
4.9. Market Outlook
5. Global Contraceptives Market Analysis and Forecast, By Product
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Key Trends
5.4. Market Value Forecast, by Product, 2017–2028
5.4.1. Contraceptives Drugs
5.4.1.1. Oral Contraceptives
5.4.1.1.1. Combined Contraceptives
5.4.1.1.2. Mini-pills
5.4.1.2. Contraceptive Injectable
5.4.1.3. Topical Contraceptive Patch
5.4.2. Contraceptive Devices
5.4.2.1. Male Contraceptive Devices
5.4.2.2. Female Contraceptive Devices
5.4.2.2.1. Female Condoms
5.4.2.2.2. Contraceptive Diaphragms
5.4.2.2.3. Contraceptive Sponges
5.4.2.2.4. Contraceptive Vaginal Rings
5.4.2.2.5. Intrauterine Devices
5.4.2.2.6. Sub-dermal Contraceptives Implants
5.4.2.2.7. Non-Surgical Permanent Contraception Devices
5.5. Market Attractiveness Analysis, By Product
6. Global Contraceptives Market Analysis and Forecast, By Distribution Channel
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Key Trends
6.4. Market Value Forecast, by Distribution Channel, 2017–2028
6.4.1. Hospital Pharmacy
6.4.1.1. Public
6.4.1.2. Private
6.4.2. Independent Pharmacy
6.4.3. Online Platform
6.4.4. Clinics
6.4.5. Others
6.5. Market Attractiveness Analysis, By Distribution Channel
7. Global Contraceptives Market Analysis and Forecast, By Region
7.1. Key Findings
7.2. Policies and Regulations
7.3. Market Value Forecast, by Region
7.3.1. North America
7.3.2. Europe
7.3.3. Asia Pacific
7.3.4. Latin America
7.3.5. Middle East and Africa
7.4. Market Attractiveness Analysis, By Country/Region
8. North America Contraceptives Market Analysis and Forecast
8.1. Introduction
8.1.1. Key Findings
8.1.2. Policies and Regulations
8.1.3. Key Trends
8.2. Market Value Forecast, by Product, 2017–2028
8.2.1. Contraceptive Drugs
8.2.1.1. Oral Contraceptives
8.2.1.1.1. Combined Contraceptives
8.2.1.1.2. Mini-pills
8.2.1.2. Contraceptive Injectable
8.2.1.3. Topical Contraceptive Patch
8.2.2. Contraceptive Devices
8.2.2.1. Male Contraceptive Devices
8.2.2.2. Female Contraceptive Devices
8.2.2.2.1. Female Condoms
8.2.2.2.2. Contraceptive Diaphragms
8.2.2.2.3. Contraceptive Sponges
8.2.2.2.4. Contraceptive Vaginal Rings
8.2.2.2.5. Intrauterine Devices
8.2.2.2.6. Sub-dermal Contraceptives Implants
8.2.2.2.7. Non-Surgical Permanent Contraception Devices
8.3. Market Value Forecast, by Distribution Channel, 2017–2028
8.3.1. Hospital Pharmacy
8.3.1.1. Public
8.3.1.2. Private
8.3.2. Independent Pharmacy
8.3.3. Online Platform
8.3.4. Clinics
8.3.5. Others
8.4. Market Value Forecast, by Country, 2017–2028
8.4.1. U.S.
8.4.2. Canada
8.5. Market Attractiveness Analysis
8.5.1. By Product
8.5.2. By Distribution Channel
8.5.3. By Country
9. Europe Contraceptives Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.1.2. Policies and Regulations
9.1.3. Key Trends
9.2. Market Value Forecast, by Product, 2017–2028
9.2.1. Contraceptive Drugs
9.2.1.1. Oral Contraceptives
9.2.1.1.1. Combined Contraceptives
9.2.1.1.2. Mini-pills
9.2.1.2. Contraceptive Injectable
9.2.1.3. Topical Contraceptive Patch
9.2.2. Contraceptive Devices
9.2.2.1. Male Contraceptive Devices
9.2.2.2. Female Contraceptive Devices
9.2.2.2.1. Female Condoms
9.2.2.2.2. Contraceptive Diaphragms
9.2.2.2.3. Contraceptive Sponges
9.2.2.2.4. Contraceptive Vaginal Rings
9.2.2.2.5. Intrauterine Devices
9.2.2.2.6. Sub-dermal Contraceptives Implants
9.2.2.2.7. Non-Surgical Permanent Contraception Devices
9.3. Market Value Forecast, by Distribution Channel, 2017–2028
9.3.1. Hospital Pharmacy
9.3.1.1. Public
9.3.1.2. Private
9.3.2. Independent Pharmacy
9.3.3. Online Platform
9.3.4. Clinics
9.3.5. Others
9.4. Market Value Forecast, by Country/Sub-region, 2017–2028
9.4.1. Germany
9.4.2. France
9.4.3. U.K.
9.4.4. Spain
9.4.5. Italy
9.4.6. Russia
9.4.7. Rest of Europe
9.5. Market Attractiveness Analysis
9.5.1. By Product
9.5.2. By Distribution Channel
9.5.3. By Country/Sub-region
10. Asia Pacific Contraceptives Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.1.2. Policies and Regulations
10.1.3. Key Trends
10.2. Market Value Forecast, by Product, 2017–2028
10.2.1. Contraceptive Drugs
10.2.1.1. Oral Contraceptives
10.2.1.1.1. Combined Contraceptives
10.2.1.1.2. Mini-pills
10.2.1.2. Contraceptive Injectable
10.2.1.3. Topical Contraceptive Patch
10.2.2. Contraceptive Devices
10.2.2.1. Male Contraceptive Devices
10.2.2.2. Female Contraceptive Devices
10.2.2.2.1. Female Condoms
10.2.2.2.2. Contraceptive Diaphragms
10.2.2.2.3. Contraceptive Sponges
10.2.2.2.4. Contraceptive Vaginal Rings
10.2.2.2.5. Intrauterine Devices
10.2.2.2.6. Sub-dermal Contraceptives Implants
10.2.2.2.7. Non-Surgical Permanent Contraception Devices
10.3. Market Value Forecast, by Distribution Channel, 2017–2028
10.3.1. Hospital Pharmacy
10.3.1.1. Public
10.3.1.2. Private
10.3.2. Independent Pharmacy
10.3.3. Online Platforms
10.3.4. Clinics
10.3.5. Others
10.4. Market Value Forecast, by Country/Sub-region, 2017–2028
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Australia & New Zealand
10.4.5. Rest of Asia Pacific
10.5. Market Attractiveness Analysis
10.5.1. By Product
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Latin America Contraceptives Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.1.2. Policies and Regulations
11.1.3. Key Trends
11.2. Market Value Forecast, by Product, 2017–2028
11.2.1. Contraceptive Drugs
11.2.1.1. Oral Contraceptives
11.2.1.1.1. Combined Contraceptives
11.2.1.1.2. Mini-pills
11.2.1.2. Contraceptive Injectable
11.2.1.3. Topical Contraceptive Patch
11.2.2. Contraceptive Devices
11.2.2.1. Male Contraceptive Devices
11.2.2.2. Female Contraceptive Devices
11.2.2.2.1. Female Condoms
11.2.2.2.2. Contraceptive Diaphragms
11.2.2.2.3. Contraceptive Sponges
11.2.2.2.4. Contraceptive Vaginal Rings
11.2.2.2.5. Intrauterine Devices
11.2.2.2.6. Sub-dermal Contraceptives Implants
11.2.2.2.7. Non-Surgical Permanent Contraception Devices
11.3. Market Value Forecast, by Distribution Channel, 2017–2028
11.3.1. Hospital Pharmacy
11.3.1.1. Public
11.3.1.2. Private
11.3.2. Independent Pharmacy
11.3.3. Online Platforms
11.3.4. Clinics
11.3.5. Others
11.4. Market Value Forecast, by Country/Sub-region, 2017–2028
11.4.1. Brazil
11.4.2. Mexico
11.4.3. Rest of Latin America
11.5. Market Attractiveness Analysis
11.5.1. By Product
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Middle East and Africa Contraceptives Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.1.2. Policies and Regulations
12.1.3. Key Trends
12.2. Market Value Forecast, by Product, 2017–2028
12.2.1. Contraceptive Drugs
12.2.1.1. Oral Contraceptives
12.2.1.1.1. Combined Contraceptives
12.2.1.1.2. Mini-pills
12.2.1.2. Contraceptive Injectable
12.2.1.3. Topical Contraceptive Patch
12.2.2. Contraceptive Devices
12.2.2.1. Male Contraceptive Devices
12.2.2.2. Female Contraceptive Devices
12.2.2.2.1. Female Condoms
12.2.2.2.2. Contraceptive Diaphragms
12.2.2.2.3. Contraceptive Sponges
12.2.2.2.4. Contraceptive Vaginal Rings
12.2.2.2.5. Intrauterine Devices
12.2.2.2.6. Sub-dermal Contraceptives Implants
12.2.2.2.7. Non-Surgical Permanent Contraception Devices
12.3. Market Value Forecast, by End User, 2017–2028
12.3.1. Hospital Pharmacy
12.3.1.1. Public
12.3.1.2. Private
12.3.2. Independent Pharmacy
12.3.3. Online Platform
12.3.4. Clinics
12.3.5. Others
12.4. Market Value Forecast, by Country /Sub-region, 2017–2028
12.4.1. GCC Countries
12.4.2. South Africa
12.4.3. Rest of Middle East and Africa
12.5. Market Attractiveness Analysis
12.5.1. By Product
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Competition Landscape
13.1. Market Player - Competition Matrix (by tier and size of companies)
13.2. Market Share Analysis, by Company, 2020
13.3. Company Profiles
13.3.1. Merck & Co., Inc.
13.3.1.1. Overview
13.3.1.2. Financials
13.3.1.3. Recent Developments
13.3.1.4. Strategy
13.3.2. Cipla, Inc.
13.3.2.1. Overview
13.3.2.2. Financials
13.3.2.3. Recent Developments
13.3.2.4. Strategy
13.3.3. Allergan plc
13.3.3.1. Overview
13.3.3.2. Financials
13.3.3.3. Recent Developments
13.3.3.4. Strategy
13.3.4. Bayer AG
13.3.4.1. Overview
13.3.4.2. Financials
13.3.4.3. Recent Developments
13.3.4.4. Strategy
13.3.5. HLL Lifecare Limited
13.3.5.1. Overview
13.3.5.2. Financials
13.3.5.3. Recent Developments
13.3.5.4. Strategy
13.3.6. Mankind Pharma
13.3.6.1. Overview
13.3.6.2. Financials
13.3.6.3. Recent Developments
13.3.6.4. Strategy
13.3.7. Pfizer, Inc.
13.3.7.1. Overview
13.3.7.2. Financials
13.3.7.3. Recent Developments
13.3.7.4. Strategy
13.3.8. Teva Pharmaceutical Industries Ltd.
13.3.8.1. Overview
13.3.8.2. Financials
13.3.8.3. Recent Developments
13.3.8.4. Strategy
13.3.9. Mithra Pharmaceuticals
13.3.9.1. Overview
13.3.9.2. Financials
13.3.9.3. Recent Developments
13.3.9.4. Strategy
13.3.10. Janssen Pharmaceutical Company
13.3.10.1. Overview
13.3.10.2. Financials
13.3.10.3. Recent Developments
13.3.10.4. Strategy
13.3.11. Reckitt Benckiser Group plc
13.3.11.1. Overview
13.3.11.2. Financials
13.3.11.3. Recent Developments
13.3.11.4. Strategy